Kawahira M, Kanmura S, Mizuno K, Machida K, et al. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. PLoS One 2022;17:e0267572.
PMID: 35482642